Skip to main navigation menu Skip to main content Skip to site footer

CHANGES IN ELASTOGRAPHY PARAMETERS IN PATIENTS WITH HEPATITIS C AFTER THE USE OF TRADITIONAL FOLK REMEDIES

Abstract

 Background: Hepatitis C virus (HCV) infection often leads to progressive liver fibrosis, which can be non-invasively assessed by elastography. Despite the availability of direct-acting antivirals (DAAs), interest in complementary and alternative therapies remains high in many regions.
Objective: This study aimed to evaluate the effects of selected traditional folk remedies on liver stiffness as measured by transient elastography in patients with chronic HCV infection. Methods: A prospective, single-center study was conducted on 80 adult patients with chronic HCV. Patients in the intervention group (n=40) received a standardized regimen of herbal extracts (based on commonly used folk remedies), while the control group (n=40) received no additional herbal therapy. All patients were on standard antiviral therapy. Liver elastography (FibroScan®) was performed at baseline and at 12 weeks post-intervention. Biochemical markers (ALT, AST) and patient-reported outcomes were also recorded.
Results: Compared with controls, the intervention group demonstrated a modest but statistically significant reduction in liver stiffness values (mean difference -1.2 kPa, p=0.03). Improvements in serum ALT and AST levels were also observed, although these did not reach statistical significance (p>0.05). No serious adverse events were reported, and overall tolerability was high. Conclusion: The addition of certain traditional folk remedies to standard antiviral therapy may contribute to mild improvements in liver elasticity in patients with chronic HCV. Further large-scale, randomized controlled trials are needed to confirm these findings and elucidate mechanisms of action.

Keywords

folk medicine, traditional remedies, herbal therapy, milk thistle, antiviral activity, liver health.

DOWNLOAD PDF

References

  1. World Health Organization. Global Hepatitis Report. Geneva: WHO; 2017.
  2. European Association for the Study of the Liver (EASL). EASL Recommendations on Treatment of Hepatitis C. J Hepatol. 2020;73(5):1170-1218.
  3. Ozaras R, Tahan V. Update on Hepatitis C: Treatment of Chronic Hepatitis C. J Clin Transl Hepatol. 2020;8(2):1-10.
  4. Flora K, Hahn M, Rosen H, Benner K. Milk Thistle (Silybum marianum) for the Therapy of Liver Disease. Am J Gastroenterol. 1998;93(2):139-143.
  5. Yang EJ, Kim SS, Lee MJ. Anti-Inflammatory and Anti-Fibrotic Effects of Curcumin in Experimental Models of Liver Disease. Phytomedicine. 2019;59:152912.
  6. Arase Y, Ikeda K, Murashima N, et al. The Long-Term Efficacy of Glycyrrhizin in Patients with Chronic Hepatitis C. Cancer. 1997;79(8):1494-1500.
  7. Zaynobidin o’g’li, Sotvoldiyev Muzaffar. "MEASURES TO FIGHT THE EPIDEMIC." Ethiopian International Journal of Multidisciplinary Research 11, no. 03 (2024): 261-263.
  8. Bakhodirovna, Mirzakarimova Dildora, and Abdukodirov Sherzodjon Taxirovich. "CHARACTERISTICS OF RHINOVIRUS INFECTION." International journal of medical sciences 4, no. 08 (2024): 55-59.
  9. Mirzakarimova, D. B., Hodjimatova, G. M., & Abdukodirov, S. T. (2024). FEATURES OF PATHOGENESIS, CLINICAL PICTURE AND DIAGNOSIS OF CO-INFECTION OF THE LIVER WITH HEPATITIS B AND C VIRUSES. International Multidisciplinary Journal for Research & Development, 11(02).
  10. Castéra L, Foucher J, Bernard PH, et al. Pitfalls of Liver Stiffness Measurement: A 5-Year Prospective Study of 13,369 Examinations. Hepatology. 2010;51(3):828-835.
  11. Curry MP, Tapper EB. Hepatitis C Virus. BMJ. 2015;350:g7809.

Downloads

Download data is not yet available.